≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Sequelae of poliomyelitis

EFO Endpoint Browser PheWeb

AB1_SEQULAE_POLIO

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — B91
  • Hospital discharge: ICD-9 — 138
  • Hospital discharge: ICD-8 — 04[4]
  • Cause of death: ICD-10 — B91
  • Cause of death: ICD-9 — 138
  • Cause of death: ICD-8 — 04[4]

2 out of 7 registries used, show all original rules.

287

4. Check minimum number of events

None

287

5. Include endpoints

None

287

6. Filter based on genotype QC (FinnGen only)

272

Control definitions (FinnGen only)

Control exclude
AB1_SEQULEAE_OF_INFECTIONS_AND_PARASITES

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF5

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 3267 1689 1520
Only index persons 2365 1316 1049
Unadjusted period prevalence (%)
Whole population 0.05 0.05 0.04
Only index persons 0.04 0.05 0.04
Median age at first event (years)
Whole population 58.93 58.69 59.11
Only index persons 57.84 57.31 58.50

-FinnGen-

Key figures

All Female Male
Number of individuals 272 128 144
Unadjusted period prevalence (%) 0.06 0.05 0.07
Median age at first event (years) 59.70 57.98 61.23

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
287
Matched controls
2870
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
B91
ICD-10 Finland
Sequelae of poliomyelitis
4503599627370496.0
307.7
251
*
1380A
ICD-9 Finland
Late effects of acute poliomyelitis[SEQUELAE POLIOMYELITIDIS]
+∞
80.0
73
*
N70
ICPC
Poliomyelitis
+∞
60.6
56
*
04499
ICD-8 Finland
Late effects of actue poliomyelitis
+∞
57.2
53
*
L28
ICPC
Limited function/disability (L)
3.8
26.8
124
476
SPAT1229
SPAT
Assessment of need for aid
4.5
19.9
56
148
N18
ICPC
Paralysis/weakness
7.4
16.0
24
35
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
6.7
15.8
26
42
A28
ICPC
Limited function/disability NOS
2.7
13.4
106
519
M89.6
ICD-10 Finland
Osteopathy after poliomyelitis
+∞
11.5
11
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.6
10.4
74
339
Z02.7
ICD-10 Finland
Issue of medical certificate
3.5
9.2
34
107
S72.4
ICD-10 Finland
Fracture of lower end of femur
15.1
8.3
13
9
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.6
8.1
51
218
R5110, ,
SPAT
2.7
7.9
47
195
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.3
7.8
67
331
XG466
NOMESCO Finland
Sleep oxymetry
4.7
7.8
18
40
N03AX16
ATC
[U] pregabalin
2.2
7.3
80
436
M41.9
ICD-10 Finland
Scoliosis, unspecified
9.7
6.9
13
14
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
3.9
6.8
20
54
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.1
6.6
28
96
N03AE01
ATC
clonazepam; systemic
3.3
6.2
23
73

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Physical Medicine And Rehabilitation
25 [38004468]
-2.6e-01
1.1e+00
—
1.0e+50
2.7e+00
2.0e+00
1.3e+00
cases:3.16%
controls:4.05%
cases:4.74%
controls:1.70%
—
—
cases:11.86%
controls:0.00%
cases:3.60%
controls:0.24%
cases:8.13%
controls:1.15%
cases:14.41%
controls:4.28%
8
100
245
2368
12
42
241
2426
—
30
0
223
2468
9
6
241
2459
20
28
226
2410
32
95
190
2123
Outpatient Visit
OP [9202]
5.6e-02
4.8e-01
1.1e-01
4.7e+00
5.0e-01
5.3e-01
2.3e-01
cases:54.15%
controls:52.76%
cases:47.04%
controls:35.53%
cases:9.49%
controls:8.55%
cases:32.02%
controls:0.45%
cases:12.80%
controls:8.15%
cases:49.59%
controls:36.59%
cases:64.86%
controls:59.51%
137
1302
116
1166
119
877
134
1591
24
211
229
2257
81
11
172
2457
32
201
218
2264
122
892
124
1546
144
1320
78
898
Neurology
13 [38004458]
9.9e-03
9.3e-01
—
—
1.6e+00
1.6e+00
1.2e+00
cases:8.30%
controls:8.23%
cases:8.30%
controls:3.44%
—
—
—
—
cases:3.20%
controls:0.65%
cases:14.63%
controls:3.45%
cases:25.23%
controls:9.65%
21
203
232
2265
21
85
232
2383
—
—
8
16
242
2449
36
84
210
2354
56
214
166
2004
Inpatient Visit
IP [9201]
1.9e-01
1.8e-01
—
—
2.6e+00
1.2e+00
6.9e-01
cases:16.21%
controls:13.82%
cases:5.93%
controls:5.02%
—
—
—
—
cases:3.60%
controls:0.28%
cases:9.76%
controls:3.16%
cases:16.67%
controls:9.15%
41
341
212
2127
15
124
238
2344
—
—
9
7
241
2458
24
77
222
2361
37
203
185
2015
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
-1.5e-01
5.0e-02
1.6e-01
3.3e+00
8.7e-01
-3.3e-02
4.0e-02
cases:15.42%
controls:17.54%
cases:16.60%
controls:15.92%
cases:4.74%
controls:4.05%
cases:5.14%
controls:0.20%
cases:9.60%
controls:4.26%
cases:17.48%
controls:17.97%
cases:27.48%
controls:26.69%
39
433
214
2035
42
393
211
2075
12
100
241
2368
13
5
240
2463
24
105
226
2360
43
438
203
2000
61
592
161
1626
MCH [Entitic mass]
28539-5 [3035941]
-1.5e-01
5.3e-02
1.6e-01
3.3e+00
8.3e-01
-3.3e-02
4.0e-02
cases:15.42%
controls:17.54%
cases:16.60%
controls:15.88%
cases:4.74%
controls:4.05%
cases:5.14%
controls:0.20%
cases:9.20%
controls:4.22%
cases:17.48%
controls:17.97%
cases:27.48%
controls:26.69%
39
433
214
2035
42
392
211
2076
12
100
241
2368
13
5
240
2463
23
104
227
2361
43
438
203
2000
61
592
161
1626
Leukocytes [#/volume] in Blood
26464-8 [3010813]
-1.5e-01
4.4e-02
1.5e-01
3.3e+00
8.2e-01
-3.1e-02
3.8e-02
cases:15.42%
controls:17.54%
cases:16.60%
controls:16.00%
cases:4.74%
controls:4.09%
cases:5.14%
controls:0.20%
cases:9.20%
controls:4.26%
cases:17.48%
controls:17.92%
cases:27.48%
controls:26.74%
39
433
214
2035
42
395
211
2073
12
101
241
2367
13
5
240
2463
23
105
227
2360
43
437
203
2001
61
593
161
1625
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
-1.5e-01
5.0e-02
1.6e-01
3.3e+00
8.2e-01
-3.3e-02
4.0e-02
cases:15.42%
controls:17.54%
cases:16.60%
controls:15.92%
cases:4.74%
controls:4.05%
cases:5.14%
controls:0.20%
cases:9.20%
controls:4.26%
cases:17.48%
controls:17.97%
cases:27.48%
controls:26.69%
39
433
214
2035
42
393
211
2075
12
100
241
2368
13
5
240
2463
23
105
227
2360
43
438
203
2000
61
592
161
1626
Platelets [#/volume] in Blood
26515-7 [3007461]
-1.8e-01
2.1e-02
7.4e-02
3.3e+00
8.2e-01
-5.9e-02
4.2e-02
cases:15.02%
controls:17.50%
cases:16.21%
controls:15.92%
cases:4.35%
controls:4.05%
cases:5.14%
controls:0.20%
cases:9.20%
controls:4.26%
cases:17.07%
controls:17.92%
cases:27.48%
controls:26.65%
38
432
215
2036
41
393
212
2075
11
100
242
2368
13
5
240
2463
23
105
227
2360
42
437
204
2001
61
591
161
1627
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
-1.6e-01
5.0e-02
1.4e-01
3.3e+00
8.2e-01
-3.6e-02
4.0e-02
cases:15.42%
controls:17.59%
cases:16.60%
controls:15.92%
cases:4.74%
controls:4.13%
cases:5.14%
controls:0.20%
cases:9.20%
controls:4.26%
cases:17.48%
controls:18.01%
cases:27.48%
controls:26.69%
39
434
214
2034
42
393
211
2075
12
102
241
2366
13
5
240
2463
23
105
227
2360
43
439
203
1999
61
592
161
1626
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
-1.5e-01
5.0e-02
1.6e-01
3.3e+00
8.2e-01
-3.1e-02
4.2e-02
cases:15.42%
controls:17.54%
cases:16.60%
controls:15.92%
cases:4.74%
controls:4.05%
cases:5.14%
controls:0.20%
cases:9.20%
controls:4.26%
cases:17.48%
controls:17.92%
cases:27.48%
controls:26.65%
39
433
214
2035
42
393
211
2075
12
100
241
2368
13
5
240
2463
23
105
227
2360
43
437
203
2001
61
591
161
1627
Supplier / Service Provider
OMOP5117446 [33004]
-1.8e+00
—
—
—
—
2.6e+00
3.1e+00
cases:7.11%
controls:31.36%
—
—
—
—
—
—
—
—
cases:3.25%
controls:0.25%
cases:9.91%
controls:0.50%
18
774
235
1694
—
—
—
—
8
6
238
2432
22
11
200
2207
Rehabilitation Hospital
283X00000X [38004285]
—
—
—
1.0e+50
—
—
3.6e+00
—
—
—
—
—
—
cases:15.02%
controls:0.00%
—
—
—
—
cases:7.66%
controls:0.23%
—
—
—
38
0
215
2468
—
—
17
5
205
2213
CBC panel - Blood by Automated count
58410-2 [40761511]
-2.1e-01
-1.2e-01
1.6e-01
2.5e+00
1.0e+00
-1.2e-01
5.7e-02
cases:12.65%
controls:15.15%
cases:9.88%
controls:11.02%
cases:2.37%
controls:2.03%
cases:2.37%
controls:0.20%
cases:6.00%
controls:2.19%
cases:10.16%
controls:11.28%
cases:22.07%
controls:21.10%
32
374
221
2094
25
272
228
2196
6
50
247
2418
6
5
247
2463
15
54
235
2411
25
275
221
2163
49
468
173
1750
Case Management Agency
251B00000X [38004193]
-1.0e-01
2.2e-01
2.4e-01
2.8e+00
2.8e-01
1.3e-01
6.7e-02
cases:35.18%
controls:37.56%
cases:34.78%
controls:30.02%
cases:13.83%
controls:11.18%
cases:11.86%
controls:0.81%
cases:15.60%
controls:12.21%
cases:35.77%
controls:32.85%
cases:51.35%
controls:49.68%
89
927
164
1541
88
741
165
1727
35
276
218
2192
30
20
223
2448
39
301
211
2164
88
801
158
1637
114
1102
108
1116
Limited function/disability NOS
A28 [2002000162]
9.2e-01
9.4e-01
—
—
—
1.4e+00
1.3e+00
cases:4.35%
controls:1.78%
cases:3.16%
controls:1.26%
—
—
—
—
—
—
cases:4.88%
controls:1.19%
cases:9.01%
controls:2.75%
11
44
242
2424
8
31
245
2437
—
—
—
12
29
234
2409
20
61
202
2157
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
1.5e-01
2.7e-01
—
—
2.7e+00
7.6e-01
4.2e-02
cases:5.53%
controls:4.82%
cases:3.16%
controls:2.43%
—
—
—
—
cases:4.00%
controls:0.28%
cases:5.69%
controls:2.75%
cases:8.11%
controls:7.80%
14
119
239
2349
8
60
245
2408
—
—
10
7
240
2458
14
67
232
2371
18
173
204
2045
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
-1.4e-01
5.8e-01
—
—
2.5e+00
6.4e-01
2.8e-02
cases:3.56%
controls:4.05%
cases:3.56%
controls:2.03%
—
—
—
—
cases:2.40%
controls:0.20%
cases:4.47%
controls:2.42%
cases:6.76%
controls:6.58%
9
100
244
2368
9
50
244
2418
—
—
6
5
244
2460
11
59
235
2379
15
146
207
2072
Laboratory Visit
OMOP4822461 [32036]
-1.5e-01
1.0e-02
4.2e-01
2.5e+00
5.7e-01
7.0e-02
8.1e-02
cases:16.21%
controls:18.35%
cases:18.18%
controls:18.03%
cases:9.88%
controls:6.73%
cases:5.53%
controls:0.49%
cases:12.00%
controls:7.18%
cases:21.54%
controls:20.39%
cases:30.18%
controls:28.49%
41
453
212
2015
46
445
207
2023
25
166
228
2302
14
12
239
2456
30
177
220
2288
53
497
193
1941
67
632
155
1586
Geriatric Medicine
38 [38004478]
—
—
—
—
—
2.3e+00
6.3e-01
—
—
—
—
—
—
—
—
—
—
cases:2.44%
controls:0.25%
cases:2.25%
controls:1.22%
—
—
—
—
—
6
6
240
2432
5
27
217
2191
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
7.5e-01
6.3e-01
—
—
2.3e+00
—
1.6e-01
cases:3.95%
controls:1.90%
cases:2.77%
controls:1.50%
—
—
—
—
cases:2.80%
controls:0.28%
—
—
cases:4.95%
controls:4.24%
10
47
243
2421
7
37
246
2431
—
—
7
7
243
2458
—
11
94
211
2124
Lumbar spine MRI examination with high intensity magnet
NA3BG [2001307034]
—
-1.0e+50
—
—
—
—
2.2e+00
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:3.60%
controls:0.41%
—
0
6
253
2462
—
—
—
—
8
9
214
2209
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
4.4e-03
4.1e-01
—
—
2.1e+00
7.0e-01
4.5e-01
cases:5.53%
controls:5.51%
cases:3.56%
controls:2.39%
—
—
—
—
cases:3.20%
controls:0.41%
cases:5.28%
controls:2.71%
cases:10.81%
controls:7.17%
14
136
239
2332
9
59
244
2409
—
—
8
10
242
2455
13
66
233
2372
24
159
198
2059
Voluntary or Charitable Agency
251V00000X [38004202]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.70%
controls:0.36%
—
—
—
—
—
—
6
8
216
2210
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
-1.2e-01
6.1e-01
1.3e+00
—
2.0e+00
7.5e-02
2.6e-01
cases:6.32%
controls:7.05%
cases:5.53%
controls:3.08%
cases:2.37%
controls:0.65%
—
—
cases:2.40%
controls:0.32%
cases:3.66%
controls:3.40%
cases:11.26%
controls:8.88%
16
174
237
2294
14
76
239
2392
6
16
247
2452
—
6
8
244
2457
9
83
237
2355
25
197
197
2021
Neurosurgery
14 [38004459]
6.0e-02
1.5e+00
—
—
—
1.9e+00
7.4e-01
cases:1.98%
controls:1.86%
cases:2.77%
controls:0.61%
—
—
—
—
—
—
cases:4.07%
controls:0.62%
cases:3.15%
controls:1.53%
5
46
248
2422
7
15
246
2453
—
—
—
10
15
236
2423
7
34
215
2184
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
3.3e-01
6.5e-01
—
—
1.9e+00
7.1e-01
5.1e-01
cases:6.72%
controls:4.90%
cases:5.14%
controls:2.76%
—
—
—
—
cases:2.80%
controls:0.45%
cases:5.69%
controls:2.87%
cases:10.81%
controls:6.76%
17
121
236
2347
13
68
240
2400
—
—
7
11
243
2454
14
70
232
2368
24
150
198
2068
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
—
—
—
—
—
1.8e+00
7.4e-01
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:0.53%
cases:2.70%
controls:1.31%
—
—
—
—
—
8
13
238
2425
6
29
216
2189
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
-8.7e-02
2.4e-01
—
—
1.7e+00
-5.7e-02
-9.7e-02
cases:11.07%
controls:11.95%
cases:8.70%
controls:6.97%
—
—
—
—
cases:4.80%
controls:0.93%
cases:7.32%
controls:7.71%
cases:16.22%
controls:17.58%
28
295
225
2173
22
172
231
2296
—
—
12
23
238
2442
18
188
228
2250
36
390
186
1828
Diabetes, insulin-treated
103 [2001600103]
—
1.7e+00
—
—
—
—
3.5e-01
—
—
cases:3.16%
controls:0.61%
—
—
—
—
—
—
—
—
cases:4.05%
controls:2.89%
—
8
15
245
2453
—
—
—
—
9
64
213
2154
hydroxyzine; oral, parenteral
N05BB01 [21604590]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.50%
controls:1.04%
—
—
—
—
—
—
10
23
212
2195
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
7.0e-02
3.9e-02
—
—
1.4e+00
1.0e-01
1.6e-01
cases:9.88%
controls:9.28%
cases:5.93%
controls:5.71%
—
—
—
—
cases:4.80%
controls:1.22%
cases:6.91%
controls:6.28%
cases:15.32%
controls:13.30%
25
229
228
2239
15
141
238
2327
—
—
12
30
238
2435
17
153
229
2285
34
295
188
1923
gabapentin; oral
N02BF01 [955005]
—
7.6e-01
—
—
—
1.4e+00
6.5e-01
—
—
cases:1.98%
controls:0.93%
—
—
—
—
—
—
cases:4.47%
controls:1.19%
cases:4.95%
controls:2.66%
—
5
23
248
2445
—
—
—
11
29
235
2409
11
59
211
2159
Home Visit
OMOP4822459 [581476]
1.9e-01
8.0e-01
5.8e-01
—
1.4e+00
6.4e-01
7.1e-01
cases:5.14%
controls:4.29%
cases:6.32%
controls:2.96%
cases:2.37%
controls:1.34%
—
—
cases:4.40%
controls:1.18%
cases:6.50%
controls:3.53%
cases:12.16%
controls:6.40%
13
106
240
2362
16
73
237
2395
6
33
247
2435
—
11
29
239
2436
16
86
230
2352
27
142
195
2076
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
-4.9e-02
1.8e-01
5.2e-01
—
1.3e+00
2.7e-01
8.6e-02
cases:13.04%
controls:13.61%
cases:11.46%
controls:9.76%
cases:3.56%
controls:2.15%
—
—
cases:7.20%
controls:2.11%
cases:13.41%
controls:10.54%
cases:20.72%
controls:19.34%
33
336
220
2132
29
241
224
2227
9
53
244
2415
—
18
52
232
2413
33
257
213
2181
46
429
176
1789
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
4.1e-01
1.0e+00
—
—
1.2e+00
1.2e+00
5.4e-01
cases:7.91%
controls:5.39%
cases:5.53%
controls:2.07%
—
—
—
—
cases:2.00%
controls:0.61%
cases:6.10%
controls:1.97%
cases:9.91%
controls:6.04%
20
133
233
2335
14
51
239
2417
—
—
5
15
245
2450
15
48
231
2390
22
134
200
2084
Limited function/disability (L)
L28 [2002000647]
6.9e-01
9.9e-01
—
—
—
1.1e+00
1.2e+00
cases:3.56%
controls:1.82%
cases:2.37%
controls:0.89%
—
—
—
—
—
—
cases:3.25%
controls:1.11%
cases:9.01%
controls:3.02%
9
45
244
2423
6
22
247
2446
—
—
—
8
27
238
2411
20
67
202
2151
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
3.9e-01
—
—
—
—
9.7e-01
1.1e+00
cases:2.37%
controls:1.62%
—
—
—
—
—
—
—
—
cases:2.03%
controls:0.78%
cases:5.86%
controls:1.94%
6
40
247
2428
—
—
—
—
5
19
241
2419
13
43
209
2175
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
-1.4e-01
-6.0e-03
1.1e-01
—
1.1e+00
2.6e-02
7.2e-02
cases:14.62%
controls:16.45%
cases:14.23%
controls:14.30%
cases:3.56%
controls:3.20%
—
—
cases:9.20%
controls:3.16%
cases:15.85%
controls:15.50%
cases:26.58%
controls:25.20%
37
406
216
2062
36
353
217
2115
9
79
244
2389
—
23
78
227
2387
39
378
207
2060
59
559
163
1659
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-2.8e-02
1.2e-01
4.9e-01
—
1.1e+00
1.9e-01
-1.1e-03
cases:12.25%
controls:12.56%
cases:11.86%
controls:10.62%
cases:4.35%
controls:2.71%
—
—
cases:7.20%
controls:2.56%
cases:13.82%
controls:11.69%
cases:19.82%
controls:19.84%
31
310
222
2158
30
262
223
2206
11
67
242
2401
—
18
63
232
2402
34
285
212
2153
44
440
178
1778
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
-1.5e-01
-1.9e-02
3.1e-01
—
1.1e+00
4.4e-02
8.5e-02
cases:14.62%
controls:16.53%
cases:14.23%
controls:14.47%
cases:4.35%
controls:3.24%
—
—
cases:9.20%
controls:3.41%
cases:16.26%
controls:15.67%
cases:27.03%
controls:25.38%
37
408
216
2060
36
357
217
2111
11
80
242
2388
—
23
84
227
2381
40
382
206
2056
60
563
162
1655
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
7.3e-02
1.8e-01
2.3e-01
—
1.0e+00
1.6e-01
2.9e-01
cases:11.46%
controls:10.74%
cases:11.46%
controls:9.76%
cases:3.56%
controls:2.84%
—
—
cases:6.80%
controls:2.60%
cases:12.20%
controls:10.54%
cases:20.72%
controls:16.41%
29
265
224
2203
29
241
224
2227
9
70
244
2398
—
17
64
233
2401
30
257
216
2181
46
364
176
1854
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
-2.1e-01
-2.6e-02
2.2e-01
—
9.8e-01
2.6e-02
1.1e-01
cases:14.23%
controls:17.06%
cases:15.02%
controls:15.36%
cases:4.74%
controls:3.85%
—
—
cases:10.00%
controls:4.02%
cases:17.48%
controls:17.10%
cases:28.38%
controls:26.15%
36
421
217
2047
38
379
215
2089
12
95
241
2373
—
25
99
225
2366
43
417
203
2021
63
580
159
1638
calcium (different salts in combination); oral
A12AA20 [21600872]
2.3e-01
1.2e-01
—
—
1.4e-01
3.5e-01
7.2e-01
cases:7.91%
controls:6.36%
cases:5.93%
controls:5.31%
—
—
—
—
cases:2.00%
controls:1.74%
cases:8.13%
controls:5.87%
cases:15.77%
controls:8.39%
20
157
233
2311
15
131
238
2337
—
—
5
43
245
2422
20
143
226
2295
35
186
187
2032
Inpatient Hospital
21 [8717]
1.6e-01
2.1e-01
7.9e-01
—
6.5e-01
4.1e-01
6.0e-01
cases:31.23%
controls:27.88%
cases:13.04%
controls:10.82%
cases:3.16%
controls:1.46%
—
—
cases:3.20%
controls:1.70%
cases:14.63%
controls:10.25%
cases:41.89%
controls:28.27%
79
688
174
1780
33
267
220
2201
8
36
245
2432
—
8
42
242
2423
36
250
210
2188
93
627
129
1591
Other specified hypothyroidism
E03.89 [2000501408]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
9
222
2209
Gout, unspecified
M10.9 [45543454]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
0
9
253
2459
—
—
—
—
0
5
246
2433
—
Ova and parasites identified in Stool by Light microscopy
10704-5 [3003327]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
Humerus X-ray examination
NB6AA [2001307259]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
—
—
betahistine; oral
N07CA01 [21604833]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
9
253
2459
—
0
5
250
2460
—
—
Taking care of patient’s/customer’s hygiene
SPAT1137 [2001700238]
—
—
—
—
—
—
9.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.25%
controls:0.86%
—
—
—
—
—
—
5
19
217
2199
hydrocortisone buteprate
D07AB11 [21602115]
2.4e-03
5.2e-01
-1.0e+50
—
—
3.8e-01
3.5e-01
cases:5.93%
controls:5.92%
cases:2.77%
controls:1.66%
cases:0.00%
controls:0.28%
—
—
—
—
cases:2.85%
controls:1.97%
cases:8.56%
controls:6.18%
15
146
238
2322
7
41
246
2427
0
7
253
2461
—
—
7
48
239
2390
19
137
203
2081
paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]
5.7e-01
1.4e+00
—
—
—
—
-9.3e-04
cases:3.95%
controls:2.27%
cases:1.98%
controls:0.49%
—
—
—
—
—
—
—
—
cases:2.70%
controls:2.71%
10
56
243
2412
5
12
248
2456
—
—
—
—
6
60
216
2158
Insulin glargine 300 U / ml
177 [2001600176]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
—
General and Unspecified, Result test/procedure
A60 [2002000194]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
0
5
253
2463
—
—
—
—
—
0
7
222
2211
Pharmacy visit
OMOP4822462 [581458]
-8.6e-02
1.9e-01
1.8e-01
-1.0e-01
3.8e-02
1.3e-01
4.5e-02
cases:71.54%
controls:73.26%
cases:73.12%
controls:69.25%
cases:43.87%
controls:39.55%
cases:1.98%
controls:2.19%
cases:40.80%
controls:39.88%
cases:75.61%
controls:73.05%
cases:86.04%
controls:85.48%
181
1808
72
660
185
1709
68
759
111
976
142
1492
5
54
248
2414
102
983
148
1482
186
1781
60
657
191
1896
31
322
Pain in joint
M25.5 [45586941]
6.9e-01
—
—
—
—
—
-1.7e-01
cases:3.56%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
cases:2.25%
controls:2.66%
9
45
244
2423
—
—
—
—
—
5
59
217
2159
Campylobacter sp identified in Tissue by Organism specific culture
20740-7 [3006418]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
253
2459
—
—
—
—
—
—
Rhinopharyngoscopy
UDH02 [2001301680]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
253
2460
—
—
—
—
—
—
Constipation caused by slow bowel passage (SCT)
K59.00 [2000502924]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
222
2213
Cardiology
6 [38004451]
4.8e-02
-2.3e-01
—
1.0e+50
—
4.9e-01
6.1e-02
cases:8.30%
controls:7.94%
cases:3.56%
controls:4.42%
—
—
cases:1.98%
controls:0.00%
—
—
cases:5.69%
controls:3.57%
cases:9.91%
controls:9.38%
21
196
232
2272
9
109
244
2359
—
5
0
248
2468
—
14
87
232
2351
22
208
200
2010
Injury of muscle(s) and tendon(s) of the rotator cuff of shoulder
S46.0 [45544769]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.93%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
0
23
253
2445
0
6
253
2462
—
—
—
—
—
Other local analgesia
WX199 [2001310775]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
222
2213
Sequelae of intracerebral haemorrhage
I69.1 [45538404]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
—
pH of Blood
11558-4 [3010421]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
253
2461
—
—
—
—
—
—
Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10886-0 [3005013]
-2.7e-01
2.0e-01
-1.0e+50
—
—
—
1.4e-01
cases:2.37%
controls:3.08%
cases:1.98%
controls:1.62%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:4.50%
controls:3.92%
6
76
247
2392
5
40
248
2428
0
6
253
2462
—
—
—
10
87
212
2131
pivmecillinam; oral
J01CA08 [21602827]
-4.5e-01
1.9e-01
—
—
-1.0e+50
-8.8e-02
3.1e-01
cases:3.56%
controls:5.47%
cases:2.77%
controls:2.31%
—
—
—
—
cases:0.00%
controls:0.20%
cases:2.03%
controls:2.21%
cases:9.01%
controls:6.76%
9
135
244
2333
7
57
246
2411
—
—
0
5
250
2460
5
54
241
2384
20
150
202
2068
dexamethasone
D07AB19 [21602116]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
0
19
253
2449
—
—
—
—
0
6
246
2432
—
Ultrasound examination of uterus and parametria
LC2AE [2001306543]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
0
10
253
2458
—
—
—
—
0
5
246
2433
—
Initiation, adjustment, discontinuation or repetition of medication
SPAT1253 [2001700354]
2.2e-01
2.5e-01
—
—
—
—
6.4e-02
cases:4.35%
controls:3.53%
cases:2.37%
controls:1.86%
—
—
—
—
—
—
—
—
cases:4.50%
controls:4.24%
11
87
242
2381
6
46
247
2422
—
—
—
—
10
94
212
2124
Visual disturbance, unspecified
H53.9 [45557475]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
—
Issue of repeat prescription
Z76.0 [45542456]
—
—
—
—
—
—
4.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.70%
controls:1.71%
—
—
—
—
—
—
6
38
216
2180
antibiotics in combination with other drugs
S01AA20 [21603571]
-3.3e-03
—
—
—
—
6.6e-01
-2.6e-01
cases:5.53%
controls:5.55%
—
—
—
—
—
—
—
—
cases:2.44%
controls:1.27%
cases:5.86%
controls:7.44%
14
137
239
2331
—
—
—
—
6
31
240
2407
13
165
209
2053
Tremor, unspecified
R25.1 [45539327]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
253
2460
—
—
—
—
—
—
tinzaparin; parenteral
B01AB10 [21600981]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
0
9
253
2459
0
6
253
2462
—
—
—
—
—
amiodarone; oral, parenteral
C01BD01 [21600270]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
8
222
2210
oxycodone and naloxone; oral
N02AA55 [21604265]
—
—
—
—
—
-1.0e+50
4.7e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:2.70%
controls:1.71%
—
—
—
—
—
0
12
246
2426
6
38
216
2180
phenylpropanolamine; oral
R01BA01 [21603209]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
—
Granulocytes/Leukocytes in Synovial fluid
26522-3 [3006571]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
222
2213
Cardiac arrhythmia NOS
K80 [2002000607]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
0
12
253
2456
0
5
253
2463
—
—
—
—
0
18
222
2200
Neoplasm of uncertain or unknown behaviour: Prostate
D40.0 [45552351]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
—
—
insulin aspart; parenteral
A10AB05 [21600719]
2.5e-01
—
—
—
—
—
1.1e-01
cases:1.98%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
cases:3.15%
controls:2.84%
5
38
248
2430
—
—
—
—
—
7
63
215
2155
Blood transfusion
WW500 [2001310603]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
0
5
253
2463
—
—
—
—
—
0
5
222
2213
Lichen planus, unspecified
L43.9 [45591635]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
0
5
253
2463
—
—
—
—
—
0
5
222
2213
medroxyprogesterone; oral, parenteral
G03DA02 [21602540]
—
-1.0e+50
—
—
—
-1.0e+50
9.3e-01
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:2.70%
controls:1.08%
—
0
12
253
2456
—
—
—
0
9
246
2429
6
24
216
2194
Type 2 diabetes mellitus, with ophthalmic complications
E11.3 [45591028]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
—
Gingivitis (chronic) NOS
K05.10 [2000502717]
—
—
—
—
—
—
7.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.25%
controls:1.13%
—
—
—
—
—
—
5
25
217
2193
Removal of sutures from oral mucosa
SXB00 [2001310580]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
253
2459
—
—
—
—
—
—
tetanus toxoid, combinations with diphtheria toxoid
J07AM51 [21601317]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.50%
controls:1.26%
—
—
—
—
—
—
10
28
212
2190
Other primary coxarthrosis
M16.1 [45591741]
—
—
—
—
-1.0e+50
—
6.9e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
cases:3.60%
controls:1.85%
—
—
—
—
0
5
250
2460
—
8
41
214
2177
Fracture of other metacarpal bone
S62.3 [45554785]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
—
—
Mycobacterium sp identified in Sputum by Organism specific culture
539-7 [3027544]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
7
222
2211
Hemiplegia, unspecified
G81.9 [45562106]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
—
Laparoscopy and sterilization
1412 [2000100157]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
—
Mild depressive episode without somatic syndrome
F32.00 [2000501978]
—
—
—
—
—
-1.0e+50
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
cases:2.25%
controls:0.27%
—
—
—
—
—
0
6
246
2432
5
6
217
2212
Check up of cardiac pacemaker
XFP20 [2001303367]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
0
21
253
2447
—
—
—
—
—
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
4.1e-01
6.8e-01
—
—
—
—
7.8e-02
cases:3.56%
controls:2.39%
cases:1.98%
controls:1.01%
—
—
—
—
—
—
—
—
cases:4.95%
controls:4.60%
9
59
244
2409
5
25
248
2443
—
—
—
—
11
102
211
2116
Psoriasis vulgaris
L40.0 [45543370]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
cases:0.00%
controls:0.36%
0
8
253
2460
—
—
—
—
0
6
246
2432
0
8
222
2210
Bell palsy
G51.0 [45571815]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
—
Coloscopy
UJF32 [2001305029]
-3.7e-02
—
—
—
—
—
5.6e-01
cases:3.56%
controls:3.69%
—
—
—
—
—
—
—
—
—
—
cases:5.86%
controls:3.43%
9
91
244
2377
—
—
—
—
—
13
76
209
2142
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
4.6e-01
—
—
—
—
—
—
cases:1.98%
controls:1.26%
—
—
—
—
—
—
—
—
—
—
—
—
5
31
248
2437
—
—
—
—
—
—
Parkinson's disease and comparable movement disrorders
110 [2001600110]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
7
222
2211
Obesity due to excess calories
E66.01 [2000501501]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
0
5
246
2433
—
Standard cardiac ultrasound examination
FM1AE [2001303278]
3.9e-01
—
—
—
—
-1.0e+50
—
cases:3.95%
controls:2.71%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
10
67
243
2401
—
—
—
—
0
20
246
2418
—
Varicose veins of lower extremities with inflammation
I83.1 [45581827]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
222
2213
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
—
—
—
1.0e+50
—
1.7e+00
7.4e-01
—
—
—
—
—
—
cases:1.98%
controls:0.00%
—
—
cases:2.03%
controls:0.37%
cases:2.25%
controls:1.08%
—
—
—
5
0
248
2468
—
5
9
241
2429
5
24
217
2194
Risk factor cardiovascular disease
K22 [2002000551]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
cases:0.00%
controls:0.86%
—
—
—
—
—
0
6
246
2432
0
19
222
2199
loratadine; oral
R06AX13 [21603514]
9.8e-01
—
—
—
—
—
—
cases:2.77%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
—
7
26
246
2442
—
—
—
—
—
—
salbutamol; inhalant
R03AC02 [21603256]
1.4e-01
2.9e-01
—
—
—
3.0e-01
8.0e-03
cases:9.88%
controls:8.71%
cases:6.72%
controls:5.11%
—
—
—
—
—
—
cases:6.10%
controls:4.59%
cases:11.26%
controls:11.18%
25
215
228
2253
17
126
236
2342
—
—
—
15
112
231
2326
25
248
197
1970
Contusion of other parts of wrist and hand
S60.2 [45602941]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
253
2461
—
—
—
—
—
—
Abdominal CT examination both without and with contrast
JN3CD [2001305561]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
—
—
Adjuvant radiotherapy
WF003 [2001310702]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
—
Rheumatology
66 [38004491]
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:1.35%
—
—
—
—
—
—
0
9
250
2456
0
33
246
2405
—
chlorphenamine, combinations
R06AB54 [21603468]
—
—
—
—
—
—
4.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.15%
controls:2.03%
—
—
—
—
—
—
7
45
215
2173
Primary total prosthetic replacement of hip joint using hybrid technique
NFB40 [2001307922]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
6
222
2212
ticagrelor; oral
B01AC24 [40252640]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
253
2461
—
—
—
—
—
—
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
-3.7e-01
2.8e-02
—
—
—
2.4e-01
-1.9e-01
cases:4.74%
controls:6.73%
cases:4.74%
controls:4.62%
—
—
—
—
—
—
cases:6.91%
controls:5.54%
cases:8.56%
controls:10.19%
12
166
241
2302
12
114
241
2354
—
—
—
17
135
229
2303
19
226
203
1992
Hip symptom/complaint
L13 [2002000637]
—
—
—
—
—
—
7.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.50%
controls:2.21%
—
—
—
—
—
—
10
49
212
2169
Polycythaemia vera
D45 [45595761]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
222
2213
Myoglobin [Mass/volume] in Serum or Plasma
2639-3 [3005895]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
Informing family of child’s disability
SPAT1236 [2001700337]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
0
7
253
2461
—
—
—
—
—
0
7
222
2211
Degeneration of macula and posterior pole
H35.39 [2000502319]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
0
10
253
2458
—
—
—
—
—
0
9
222
2209
Cellulitis of finger and toe
L03.0 [45557691]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
0
6
246
2432
—
Fitting of hearing aid
DAX08 [2001301529]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
11
253
2457
0
5
253
2463
—
—
—
—
0
15
222
2203
Photography of fundus of the eye or interpretation of photograph
SPAT1008 [2001700109]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
0
5
253
2463
—
—
—
—
—
0
16
222
2202
clobetasol
D07AD01 [21602141]
—
—
—
—
—
—
8.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.15%
controls:1.40%
—
—
—
—
—
—
7
31
215
2187
Plantar fascial fibromatosis
M72.2 [45553265]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
0
9
253
2459
—
—
—
—
—
0
11
222
2207
mometasone; nasal
R01AD09 [21605051]
-1.8e-01
-4.6e-02
—
—
—
—
2.8e-01
cases:4.74%
controls:5.63%
cases:1.98%
controls:2.07%
—
—
—
—
—
—
—
—
cases:7.21%
controls:5.55%
12
139
241
2329
5
51
248
2417
—
—
—
—
16
123
206
2095
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
-3.4e-01
2.6e-01
—
—
—
-3.2e-01
-1.5e-01
cases:10.28%
controls:13.86%
cases:10.28%
controls:8.14%
—
—
—
—
—
—
cases:7.32%
controls:9.76%
cases:17.57%
controls:19.84%
26
342
227
2126
26
201
227
2267
—
—
—
18
238
228
2200
39
440
183
1778
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.11%
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
0
52
253
2416
0
17
253
2451
—
—
—
—
—
pneumococcus, purified polysaccharides antigen
J07AL01 [21601312]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
222
2213
Disorder of lipoprotein metabolism, unspecified
E78.9 [45581384]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
—
—
Perimetry
XCK00 [2001301380]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.81%
—
0
6
253
2462
—
—
—
0
9
246
2429
0
18
222
2200
Anaemia vit B12/folate deficiency
B81 [2002000292]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
—
Foreign body in cornea
T15.0 [45570142]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
7
222
2211
Excision of lesion of eyelid
CBB30 [2001300933]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
7
222
2211
Corneal ulcer
H16.0 [45557339]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
Bilateral salpingo-oophorectomy
LAF10 [2001306443]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
0
5
253
2463
—
—
—
—
—
0
8
222
2210
Low back symptom/complaint
L03 [2002000628]
—
1.2e+00
—
—
—
—
1.8e-01
—
—
cases:2.77%
controls:0.89%
—
—
—
—
—
—
—
—
cases:3.15%
controls:2.66%
—
7
22
246
2446
—
—
—
—
7
59
215
2159
econazole
D01AC03 [21601922]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
0
5
246
2433
—
mirtazapine; oral
N06AX11 [21604740]
-7.6e-01
-4.1e-01
—
—
—
6.3e-01
6.1e-01
cases:1.98%
controls:4.13%
cases:1.98%
controls:2.96%
—
—
—
—
—
—
cases:4.07%
controls:2.21%
cases:9.01%
controls:5.09%
5
102
248
2366
5
73
248
2395
—
—
—
10
54
236
2384
20
113
202
2105
hydrochlorothiazide; oral
C03AA03 [21601466]
-4.3e-01
—
—
—
—
5.4e-02
-1.4e-01
cases:1.98%
controls:3.00%
—
—
—
—
—
—
—
—
cases:2.03%
controls:1.93%
cases:2.25%
controls:2.57%
5
74
248
2394
—
—
—
—
5
47
241
2391
5
57
217
2161
empagliflozin; oral
A10BK03 [1123740]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
6
253
2462
—
0
5
250
2460
—
—
Sequelae of cerebral infarction
I69.3 [45533476]
—
—
—
—
—
—
3.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.25%
controls:1.53%
—
—
—
—
—
—
5
34
217
2184
cloxacillin; oral, parenteral
J01CF02 [21602854]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
—
—
Basal cell carcinoma, NOS, of skin, NOS
8090/3-C44.9 [44505057]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
0
15
253
2453
0
5
253
2463
—
—
—
—
0
13
222
2205
Heart valve disease NOS
K83 [2002000610]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
222
2213
Nutrition survey
SPAT1139 [2001700240]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
7
222
2211
Hemoglobin.gastrointestinal [Presence] in Stool
2335-8 [3016251]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.68%
—
0
6
253
2462
—
—
—
0
11
246
2427
0
15
222
2203
Two-surface restoration
SFA20 [2001310359]
-4.9e-03
—
—
—
-1.0e+50
—
3.2e-01
cases:5.93%
controls:5.96%
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
cases:10.81%
controls:8.07%
15
147
238
2321
—
—
—
0
7
250
2458
—
24
179
198
2039
Internal derangement of knee, unspecified
M23.9 [45567507]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
0
5
253
2463
—
—
—
—
0
13
222
2205
valdecoxib; oral
M01AH03 [21603994]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
253
2456
—
—
—
—
—
—
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
—
—
—
—
-1.0e+50
5.4e-02
2.9e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:2.03%
controls:1.93%
cases:5.86%
controls:4.46%
—
—
—
—
0
9
250
2456
5
47
241
2391
13
99
209
2119
Thyroid insufficiency
104 [2001600104]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.59%
—
—
—
—
—
0
5
246
2433
0
13
222
2205
Endocrinology
46 [38004485]
—
—
—
—
—
1.2e+00
4.8e-01
—
—
—
—
—
—
—
—
—
—
cases:2.85%
controls:0.86%
cases:3.15%
controls:1.98%
—
—
—
—
—
7
21
239
2417
7
44
215
2174
fluocortolone
D07AC05 [21602124]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.70%
controls:0.72%
—
—
—
—
—
—
6
16
216
2202
Radical radiotherapy
WF002 [2001310701]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
Streptococcus pyogenes Ag [Presence] in Throat
18481-2 [3033319]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
253
2460
—
—
—
—
—
—
Shoulder symptom/complaint
L08 [2002000632]
6.8e-01
—
—
—
—
—
5.5e-01
cases:1.98%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
cases:3.60%
controls:2.12%
5
25
248
2443
—
—
—
—
—
8
47
214
2171
Calculus of gallbladder with acute cholecystitis
K80.0 [45586735]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
253
2460
—
—
—
—
—
—
Other medical or dental certificate
WZA90 [2001310883]
6.5e-01
—
—
—
—
—
4.5e-01
cases:2.77%
controls:1.46%
—
—
—
—
—
—
—
—
—
—
cases:3.15%
controls:2.03%
7
36
246
2432
—
—
—
—
—
7
45
215
2173
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
D38.1 [45605357]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
222
2213
More than one and less than three hours
ZXE10 [2001311401]
3.9e-01
—
—
—
—
9.2e-01
7.7e-01
cases:5.14%
controls:3.53%
—
—
—
—
—
—
—
—
cases:2.03%
controls:0.82%
cases:7.21%
controls:3.47%
13
87
240
2381
—
—
—
—
5
20
241
2418
16
77
206
2141
lidocaine
C05AD01 [21601618]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
6
222
2212
Lactate [Moles/volume] in Arterial blood
2518-9 [3018405]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
253
2456
—
—
—
—
—
—
timolol, combinations
S01ED51 [21603705]
—
—
—
—
—
—
-1.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.25%
controls:2.71%
—
—
—
—
—
—
5
60
217
2158
carvedilol; oral
C07AG02 [21601700]
5.6e-01
—
-1.0e+50
—
—
—
4.2e-01
cases:1.98%
controls:1.13%
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
cases:2.25%
controls:1.49%
5
28
248
2440
—
0
8
253
2460
—
—
—
5
33
217
2185
Left ventricular failure
I50.1 [45543181]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
cases:0.00%
controls:0.77%
—
—
—
—
—
0
6
246
2432
0
17
222
2201
Conjunctival surface anesthesia
WX100 [2001310764]
1.5e+00
-1.0e+50
—
—
—
—
7.1e-01
cases:2.37%
controls:0.53%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
cases:2.70%
controls:1.35%
6
13
247
2455
0
7
253
2461
—
—
—
—
6
30
216
2188
solifenacin; oral
G04BD08 [21602641]
—
1.5e+00
—
—
-1.0e+50
—
—
—
—
cases:1.98%
controls:0.45%
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
5
11
248
2457
—
—
0
5
250
2460
—
—
Total body bone isotope imaging
NK6AN [2001308473]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
Other blockage of nerve
WX290 [2001310792]
-1.6e-01
—
—
—
—
1.2e+00
-1.9e-01
cases:1.98%
controls:2.31%
—
—
—
—
—
—
—
—
cases:2.44%
controls:0.74%
cases:3.15%
controls:3.79%
5
57
248
2411
—
—
—
—
6
18
240
2420
7
84
215
2134
Separate instruction to prepare for procedure
SPAT1266 [2001700367]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
0
6
253
2462
—
—
—
—
—
0
9
222
2209
progesterone; oral, parenteral, rectal, vaginal
G03DA04 [21602542]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
0
5
253
2463
—
—
—
—
—
0
7
222
2211
Mixed conductive and sensorineural hearing loss, bilateral
H90.6 [45601013]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
—
Sprain and strain of shoulder joint
S43.4 [45607418]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
222
2213
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
0
6
253
2462
—
—
—
0
10
246
2428
—
naproxcinod
M01AE18 [40254094]
2.1e-01
7.1e-01
—
—
—
5.0e-01
-2.4e-01
cases:7.91%
controls:6.52%
cases:4.35%
controls:2.19%
—
—
—
—
—
—
cases:3.66%
controls:2.26%
cases:5.41%
controls:6.76%
20
161
233
2307
11
54
242
2414
—
—
—
9
55
237
2383
12
150
210
2068
Catheterization and pressure measurement of the left side of the heart
61 [2002100118]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
—
—
Microbiological examinations
SBA00 [2001310293]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
6
222
2212
dexamethasone
D10AA03 [21602286]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
0
19
253
2449
—
—
—
—
0
6
246
2432
—
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
-1.3e-01
—
-1.0e+50
—
—
3.6e-02
6.2e-01
cases:7.51%
controls:8.47%
—
—
cases:0.00%
controls:0.32%
—
—
—
—
cases:2.85%
controls:2.75%
cases:16.22%
controls:9.42%
19
209
234
2259
—
0
8
253
2460
—
—
7
67
239
2371
36
209
186
2009
Urinary tract infection, site not specified
N39.0 [45548665]
—
—
—
—
—
—
-1.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.25%
controls:2.52%
—
—
—
—
—
—
5
56
217
2162
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
-3.6e-01
1.6e-01
1.2e+00
—
—
4.1e-01
3.8e-01
cases:6.32%
controls:8.83%
cases:5.93%
controls:5.11%
cases:2.37%
controls:0.73%
—
—
—
—
cases:6.91%
controls:4.72%
cases:16.22%
controls:11.72%
16
218
237
2250
15
126
238
2342
6
18
247
2450
—
—
17
115
229
2323
36
260
186
1958
Dental X-ray, bite-wing X-ray on one side of the mouth
EB1SA [2001301918]
-4.5e-01
—
—
—
—
—
2.9e-01
cases:2.37%
controls:3.69%
—
—
—
—
—
—
—
—
—
—
cases:4.95%
controls:3.74%
6
91
247
2377
—
—
—
—
—
11
83
211
2135
Sex hormone binding globulin [Moles/volume] in Serum or Plasma
13967-5 [3004248]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
253
2459
—
—
—
—
—
—
Pulp capping
SGC10 [2001310393]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
0
9
253
2459
—
—
—
—
—
0
5
222
2213
betamethasone
A07EA04 [21600656]
5.2e-02
-1.8e-01
—
—
-1.0e+50
—
4.2e-01
cases:5.53%
controls:5.27%
cases:1.98%
controls:2.35%
—
—
—
—
cases:0.00%
controls:0.49%
—
—
cases:7.66%
controls:5.18%
14
130
239
2338
5
58
248
2410
—
—
0
12
250
2453
—
17
115
205
2103
Alzheimer disease with late onset
G30.1 [45552521]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
14
253
2454
—
—
—
—
—
Irritable bowel syndrome without diarrhoea
K58.9 [45538539]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
Upper gastrointestinal surgery
106 [44777669]
-4.7e-02
3.3e-01
—
—
—
7.0e-01
3.5e-01
cases:5.93%
controls:6.20%
cases:3.95%
controls:2.88%
—
—
—
—
—
—
cases:5.69%
controls:2.91%
cases:10.36%
controls:7.53%
15
153
238
2315
10
71
243
2397
—
—
—
14
71
232
2367
23
167
199
2051
Other senile cataract
H25.8 [45605644]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
0
9
246
2429
—
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
9.0e-01
—
—
—
—
—
-6.1e-02
cases:5.14%
controls:2.15%
—
—
—
—
—
—
—
—
—
—
cases:2.25%
controls:2.39%
13
53
240
2415
—
—
—
—
—
5
53
217
2165
Acute sinusitis
J01 [45548098]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
6
222
2212
Kolposcopy
ULA02 [2001306679]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
7
222
2211
miconazole
S02AA13 [21605159]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
—
Haptoglobin [Mass/volume] in Serum or Plasma
4542-7 [3012336]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
megestrol; oral
L02AB01 [21603820]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
cases:0.00%
controls:0.27%
—
—
—
—
—
0
7
246
2431
0
6
222
2212
Extraction of tooth
EBA00 [2001301923]
4.2e-01
—
—
—
-1.0e+50
—
-4.6e-02
cases:3.16%
controls:2.11%
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
cases:4.05%
controls:4.24%
8
52
245
2416
—
—
—
0
5
250
2460
—
9
94
213
2124
ipratropium bromide; inhalant
R03BB01 [21603293]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
9
253
2459
—
—
—
—
—
Physiotherapy
R4110 [2001310233]
7.1e-01
1.2e+00
—
1.0e+50
—
8.5e-01
4.4e-01
cases:5.93%
controls:3.00%
cases:3.16%
controls:0.97%
—
—
cases:1.98%
controls:0.00%
—
—
cases:2.85%
controls:1.23%
cases:4.95%
controls:3.25%
15
74
238
2394
8
24
245
2444
—
5
0
248
2468
—
7
30
239
2408
11
72
211
2146
Gynecological ultrasound examination as part of clinical examination
LX1AE [2001306815]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
253
2459
—
—
—
—
—
—
Malignant tumor of the upper inner quadrant of the mammary gland,ductal tumor
C50.21 [2000500994]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
0
5
253
2463
—
—
—
—
—
0
5
222
2213
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
—
Addiction caused by alcohol UNS
F10.29 [2000501684]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
0
8
253
2460
—
—
—
—
—
0
5
222
2213
s-atenolol; oral
C07AB11 [21601693]
2.5e-01
2.8e-01
—
—
—
3.3e-01
5.5e-01
cases:2.37%
controls:1.86%
cases:1.98%
controls:1.50%
—
—
—
—
—
—
cases:2.03%
controls:1.48%
cases:3.15%
controls:1.85%
6
46
247
2422
5
37
248
2431
—
—
—
5
36
241
2402
7
41
215
2177
Essential tremor
G25.0 [45533132]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
253
2455
—
—
—
—
—
—
prednisolone
A07EA01 [21600653]
-1.2e-01
-1.4e-01
-1.0e+50
—
—
-1.7e-01
-2.1e-01
cases:6.72%
controls:7.50%
cases:3.56%
controls:4.05%
cases:0.00%
controls:0.81%
—
—
—
—
cases:3.66%
controls:4.31%
cases:8.56%
controls:10.37%
17
185
236
2283
9
100
244
2368
0
20
253
2448
—
—
9
105
237
2333
19
230
203
1988
clobetasone
D07AB01 [21602105]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
11
222
2207
Shigella sp [Presence] in Stool by Culture
82300-5 [42529406]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
253
2459
—
—
—
—
—
—
levocetirizine; oral
R06AE09 [21603498]
6.0e-01
—
—
—
—
—
—
cases:1.98%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
5
27
248
2441
—
—
—
—
—
—
Malignant neoplasm of prostate
C61 [45547509]
—
—
—
—
—
3.0e-01
1.9e-01
—
—
—
—
—
—
—
—
—
—
cases:2.03%
controls:1.52%
cases:3.15%
controls:2.61%
—
—
—
—
—
5
37
241
2401
7
58
215
2160
Deviated nasal septum
J34.2 [45562448]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
253
2461
—
—
—
—
—
—
montelukast; oral
R03DC03 [21603356]
—
—
—
—
—
—
2.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.15%
controls:2.39%
—
—
—
—
—
—
7
53
215
2165
Urinary tract ultrasound examination
KH1AE [2001306329]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
15
222
2203
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
-9.3e-02
-8.5e-02
—
—
-1.0e+50
5.0e-01
3.4e-01
cases:3.56%
controls:3.89%
cases:1.98%
controls:2.15%
—
—
—
—
cases:0.00%
controls:0.28%
cases:4.07%
controls:2.50%
cases:7.66%
controls:5.59%
9
96
244
2372
5
53
248
2415
—
—
0
7
250
2458
10
61
236
2377
17
124
205
2094
Senile cataract, unspecified
H25.9 [45552640]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
222
2213
Biopsy of endometrium
LCA06 [2001306551]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
253
2453
—
—
—
—
—
—
Percutaneous transluminal coronary angioplasty with stent (includes balloon pre-dilation)
FN2BA [2001303090]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.57%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
0
14
253
2454
0
6
253
2462
—
—
—
—
—
Carcinoma in situ: Skin of trunk
D04.5 [45576373]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
222
2213
fusidic acid
S01AA13 [21603564]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
0
5
246
2433
—
Basophils [#/volume] in Blood
26444-0 [3006315]
-3.5e-02
7.1e-02
—
—
—
3.0e-01
1.5e-01
cases:4.74%
controls:4.90%
cases:3.56%
controls:3.32%
—
—
—
—
—
—
cases:3.66%
controls:2.75%
cases:7.66%
controls:6.67%
12
121
241
2347
9
82
244
2386
—
—
—
9
67
237
2371
17
148
205
2070
alprazolam; oral
N05BA12 [21604577]
8.6e-01
1.1e+00
—
—
—
1.4e+00
8.1e-01
cases:2.37%
controls:1.01%
cases:2.37%
controls:0.81%
—
—
—
—
—
—
cases:2.85%
controls:0.70%
cases:2.70%
controls:1.22%
6
25
247
2443
6
20
247
2448
—
—
—
7
17
239
2421
6
27
216
2191
dexamethasone
S03BA01 [21605201]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.50%
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
0
37
253
2431
0
15
253
2453
—
—
—
—
—
Excision of other lesion extending through all layers of skin in head or neck
QAE10 [2001309784]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
0
14
253
2454
—
—
—
—
0
8
246
2430
—
insulin (human); parenteral
A10AB01 [21600715]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
0
5
253
2463
—
0
7
250
2458
—
—
Volume in Urine collected for unspecified duration
19153-6 [3004775]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
0
5
253
2463
—
—
—
—
—
0
6
222
2212
Impacted cerumen
H61.2 [45562307]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
17
222
2201
econazole; vaginal
G01AF05 [21602395]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
0
6
246
2432
—
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
—
—
—
—
—
—
-6.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.70%
controls:4.87%
—
—
—
—
—
—
6
108
216
2110
Sampling
SPAT1263 [2001700364]
-4.4e-01
3.3e-01
—
—
—
-1.4e-01
3.9e-01
cases:3.56%
controls:5.43%
cases:3.56%
controls:2.59%
—
—
—
—
—
—
cases:2.03%
controls:2.34%
cases:6.76%
controls:4.69%
9
134
244
2334
9
64
244
2404
—
—
—
5
57
241
2381
15
104
207
2114
Rheumatoid/seropositive arthritis
L88 [2002000707]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
0
9
253
2459
—
—
—
—
—
0
8
222
2210
escitalopram; oral
N06AB10 [21604718]
—
—
-1.0e+50
—
—
—
-9.9e-02
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
cases:2.25%
controls:2.48%
—
—
0
5
253
2463
—
—
—
5
55
217
2163
Amputation of toe
NHQ40 [2001308365]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
6
222
2212
tadalafil; oral
G04BE08 [21602653]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
0
6
253
2462
—
—
—
0
14
246
2424
—
mirabegron; oral
G04BD12 [43534790]
—
—
—
—
—
—
4.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.15%
controls:2.12%
—
—
—
—
—
—
7
47
215
2171
Right side
ZXA00 [2001311346]
6.9e-02
—
—
—
—
—
1.7e-01
cases:3.16%
controls:2.96%
—
—
—
—
—
—
—
—
—
—
cases:3.60%
controls:3.07%
8
73
245
2395
—
—
—
—
—
8
68
214
2150
Rash and other nonspecific skin eruption
R21 [45553721]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
6
222
2212
prednisone
A07EA03 [21600655]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
0
16
246
2422
—
Fund application (Nissen)
6241 [2000100939]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
—
Left side
ZXA05 [2001311347]
9.9e-02
—
—
—
—
—
4.1e-01
cases:2.77%
controls:2.51%
—
—
—
—
—
—
—
—
—
—
cases:3.15%
controls:2.12%
7
62
246
2406
—
—
—
—
—
7
47
215
2171
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.15%
controls:0.99%
—
—
—
—
—
—
7
22
215
2196
Percutaneous insertion of coronary artery stent
FN1YT [2001303064]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
0
5
246
2433
—
Benign neoplasm: Rectum
D12.8 [45595734]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
cases:0.00%
controls:0.59%
—
—
—
—
—
0
7
246
2431
0
13
222
2205
Extensive global examination
SPAT1360 [2001700461]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
Delivery in a completely normal case[PARTUS SINE COMPLICATIONE]
6500B [2000405100]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
8
222
2210
Sprain and strain of ankle
S93.4 [45550848]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
253
2459
—
—
—
—
—
—
Chronic kidney disease, unspecified
N18.9 [45553438]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
0
11
253
2457
0
6
253
2462
—
—
—
0
7
246
2431
—
Allergy, unspecified
T78.4 [45580373]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
—
Hypertension uncomplicated
K86 [2002000613]
—
—
—
—
—
-1.0e+50
4.5e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:3.15%
controls:2.03%
—
—
—
—
—
0
12
246
2426
7
45
215
2173
Contact with other and unspecified machinery
W31 [45756284]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
—
—
Elbow X-ray examination without contrast
NC1AA [2001307421]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
6
222
2212
Pain in throat
R07.0 [45592406]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
0
6
253
2462
0
5
253
2463
—
—
—
—
0
6
222
2212
Application of cast or individual aid
SPAT1210 [2001700311]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
—
betamethasone
S03BA03 [21605203]
—
-1.0e+50
—
—
—
—
3.2e-01
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
cases:3.15%
controls:2.30%
—
0
20
253
2448
—
—
—
—
7
51
215
2167
Osteo-arthrosis and allied disorders, Osteo-arthrosis, localised, primary[OSTEOARTHROSIS PRIMARIA, POLVI]
7151F [2000405800]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
—
sildenafil; oral
G04BE03 [21602648]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
Conjunctivitis, unspecified
H10.9 [45591253]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
9
222
2209
zopiclone; oral
N05CF01 [21604654]
2.8e-01
2.2e-01
—
—
—
2.3e-01
1.5e-01
cases:9.09%
controls:7.05%
cases:5.93%
controls:4.82%
—
—
—
—
—
—
cases:5.69%
controls:4.59%
cases:9.46%
controls:8.25%
23
174
230
2294
15
119
238
2349
—
—
—
14
112
232
2326
21
183
201
2035
Hypo-osmolality and hyponatraemia
E87.1 [45542779]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
—
—
Destruction of lesion of head or neck
QAA25 [2001309763]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
9
222
2209
AVR bio, stent
AB2 [2000200109]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
6
222
2212
Hearing loss, unspecified
H91.9 [45547996]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
—
fluticasone furoate; nasal
R01AD12 [21605053]
-3.5e-02
5.0e-01
—
—
—
7.7e-01
1.7e-01
cases:4.74%
controls:4.90%
cases:3.16%
controls:1.94%
—
—
—
—
—
—
cases:4.07%
controls:1.93%
cases:7.21%
controls:6.18%
12
121
241
2347
8
48
245
2420
—
—
—
10
47
236
2391
16
137
206
2081
Eye discharge
F03 [2002000401]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
0
8
253
2460
—
—
—
—
0
5
246
2433
—
Old myocardial infarction
I25.2 [45601025]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.31%
—
—
—
—
—
—
0
29
222
2189
Arthrocentesis, unspecified region, unspecified region
TNX10 [2001308560]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
13
222
2205
Internal Medicine
11 [38004456]
2.2e-01
9.4e-02
7.1e-01
—
—
1.6e-01
2.2e-01
cases:25.30%
controls:21.35%
cases:9.49%
controls:8.71%
cases:3.16%
controls:1.58%
—
—
—
—
cases:10.16%
controls:8.78%
cases:27.03%
controls:22.90%
64
527
189
1941
24
215
229
2253
8
39
245
2429
—
—
25
214
221
2224
60
508
162
1710
ferrous sulfate; oral
B03AA07 [21601086]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
222
2213
Fall into hole or other opening in surface
E883A [2000408881]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
—
—
Microorganisms panel - Urine sediment
58435-9 [40761536]
-1.0e+50
—
—
—
—
—
7.4e-01
cases:0.00%
controls:0.89%
—
—
—
—
—
—
—
—
—
—
cases:2.70%
controls:1.31%
0
22
253
2446
—
—
—
—
—
6
29
216
2189
ABO and Rh group [Type] in Blood
882-1 [3003694]
-1.4e-01
6.8e-01
—
—
—
—
4.3e-01
cases:1.98%
controls:2.27%
cases:1.98%
controls:1.01%
—
—
—
—
—
—
—
—
cases:3.15%
controls:2.07%
5
56
248
2412
5
25
248
2443
—
—
—
—
7
46
215
2172
Emergency visit or other similar visit involving procedures
WYA05 [2001310871]
—
—
—
—
—
—
2.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.86%
controls:4.64%
—
—
—
—
—
—
13
103
209
2115
Plugged feeling ear
H13 [2002000480]
1.8e-01
—
—
—
—
—
-4.4e-02
cases:1.98%
controls:1.66%
—
—
—
—
—
—
—
—
—
—
cases:3.15%
controls:3.29%
5
41
248
2427
—
—
—
—
—
7
73
215
2145
Removal wax from ear
TDA90 [2001301543]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
—
Treatment plan or consultation
WZC00 [2001310885]
—
—
—
—
—
—
6.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.41%
controls:2.84%
—
—
—
—
—
—
12
63
210
2155
Bronchiectasis
J47 [45605889]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
253
2461
—
—
—
—
—
—
Pulmonary embolism with mention of acute cor pulmonale
I26.0 [45567169]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
6
222
2212
pregabalin; oral
N02BF02 [955152]
5.9e-01
7.6e-01
—
—
—
8.7e-01
8.6e-01
cases:3.95%
controls:2.23%
cases:3.56%
controls:1.70%
—
—
—
—
—
—
cases:3.66%
controls:1.56%
cases:6.76%
controls:2.98%
10
55
243
2413
9
42
244
2426
—
—
—
9
38
237
2400
15
66
207
2152
Hysteroscopy
1350 [2000100145]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
222
2213
Other and unspecified infectious diseases
B99 [45590874]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
222
2213
Changing form of teeth in prepation for prosthodontic work
SPA00 [2001310458]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
222
2213
Schizophrenia, unspecified
F20.9 [45576533]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.28%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
0
7
253
2461
0
6
253
2462
—
—
—
—
—
Anaemia, unspecified
D64.9 [45600610]
—
—
—
—
—
—
9.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.15%
controls:1.31%
—
—
—
—
—
—
7
29
215
2189
Tinea pedis
B35.3 [45581158]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
0
5
253
2463
—
—
—
—
—
0
5
222
2213
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
—
Stenosis and insufficiency of lacrimal passages
H04.5 [45581556]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
0
7
253
2461
—
—
—
—
—
0
6
222
2212
Complement C3 [Mass/volume] in Serum or Plasma
4485-9 [3000620]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
253
2461
—
—
—
—
—
—
galantamine; oral
N06DA04 [21604797]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.28%
cases:0.00%
controls:0.32%
—
—
—
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.29%
cases:0.00%
controls:0.59%
0
7
253
2461
0
8
253
2460
—
—
0
6
250
2459
0
7
246
2431
0
13
222
2205
Other fall from one level to another
W17 [45756255]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
8
222
2210
Cathetrisation of pulmonal artery
TFB00 [2001302495]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
222
2213
Gout
T92 [2002001133]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
6
222
2212
Other specified medical care
Z51.88 [2000503765]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
253
2461
—
—
—
—
—
—
Contusion of lower back and pelvis
S30.0 [45549279]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
—
—
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
4.3e-01
2.0e+00
—
1.0e+50
—
—
—
cases:1.98%
controls:1.30%
cases:1.98%
controls:0.28%
—
—
cases:2.37%
controls:0.00%
—
—
—
—
—
—
5
32
248
2436
5
7
248
2461
—
6
0
247
2468
—
—
—
Sprain and strain of other and unspecified parts of knee
S83.6 [45579536]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
253
2462
—
—
—
—
—
—
Iron deficiency anaemia secondary to blood loss (chronic)
D50.0 [45566697]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
—
Excessive attrition of teeth
K03.0 [45601139]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
253
2463
—
—
—
—
—
—
tamsulosin and dutasteride
G04CA52 [21602673]
—
5.3e-01
—
—
—
3.5e-01
—
—
—
cases:1.98%
controls:1.18%
—
—
—
—
—
—
cases:2.03%
controls:1.44%
—
—
—
5
29
248
2439
—
—
—
5
35
241
2403
—
Skin colour change
S08 [2002000973]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
253
2455
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
83
549
1.72
3.97
3.8
4.2
78.14
260.34
ng/l
1.52
75
481
154
1202
1.61
3.81
6.0
4.8
33.73
34.83
g/l
1.51
143
1120
44
248
1.91
3.54
1.6
2.2
0.22
0.21
g/l
0.22
38
227
52
323
1.74
3.06
5.5
4.3
19.08
41.48
ug/l
0.37
43
278
57
365
1.70
3.01
6.1
7.0
1.98
0.93
mmol/l
1.34
51
303
141
1126
1.50
2.86
2.8
2.4
80.48
79.70
nmol/l
0.12
127
987
168
1392
1.50
2.83
9.3
7.1
1.22
1.21
mmol/l
0.54
148
1201
57
374
1.65
2.75
6.3
6.9
7.42
7.42
ph
0.18
27
227
31
171
1.91
2.67
4.8
7.3
25.99
24.56
mmol/l
1.26
31
171
41
250
1.75
2.58
6.9
8.1
—
—
—
0
0
152
1250
1.46
2.56
7.4
6.5
1.21
1.21
mmol/l
0.01
141
1141
29
159
1.92
2.55
1.2
1.2
—
—
—
0
0
107
827
1.47
2.47
4.2
4.4
—
—
—
0
0
12
46
2.68
2.39
1.2
1.1
—
—
—
0
0
104
809
1.45
2.29
5.6
5.9
—
—
—
0
0
162
1369
1.42
2.24
7.9
6.9
11.38
12.09
umol/l
0.44
153
1301
39
245
1.68
2.22
3.5
2.3
34.09
33.19
u/l
0.06
34
202
96
741
1.44
2.19
7.8
6.4
—
—
—
0
0
109
862
1.43
2.18
5.1
4.4
7.39
7.40
ph
0.40
78
630
80
600
1.46
2.11
4.4
3.1
2.48
2.46
mmol/l
0.86
73
537
29
465
0.58
2.06
5.6
5.6
—
—
—
0
0
8
26
3.13
2.03
1.8
1.5
17.31
35.32
ng/l
—
8
26
8
187
0.41
2.01
1.6
1.7
—
—
—
0
0
17
85
2.06
1.94
2.9
3.9
3.86
1.59
index
—
7
51
114
933
1.37
1.80
4.6
3.3
2.35
2.35
mmol/l
0.04
104
835
7
24
2.96
1.73
1.0
1.7
8.94
10.98
%
—
7
24
104
844
1.36
1.71
1.8
1.8
19.58
20.98
nmol/l
0.48
86
687
62
464
1.43
1.64
4.2
3.4
3.24
1.89
e6/l
0.31
34
243
144
1235
1.33
1.63
2.5
2.2
90.69
94.00
pmol/l
0.35
79
643
151
1709
0.75
1.57
4.1
4.2
15.59
15.16
pmol/l
1.21
140
1508
187
1685
1.32
1.40
5.4
5.2
—
2.34
—
0
6
204
1863
1.33
1.37
9.6
8.7
85.50
80.24
u/l
0.55
195
1757
5
17
2.97
1.36
1.6
2.1
—
—
—
0
0
0
37
0.00
1.35
0.0
1.5
—
—
—
0
0
13
230
0.54
1.34
3.4
4.7
1.57
0.86
%
—
7
85
29
194
1.55
1.33
4.6
4.3
—
—
—
0
0
88
723
1.31
1.29
2.7
2.2
2.75
3.05
mg/l
0.61
76
628
12
215
0.54
1.29
3.3
4.8
0.00
0.13
%
—
6
70
107
907
1.29
1.24
4.1
3.7
—
—
—
0
0
115
985
1.28
1.23
5.4
4.5
761.75
125.99
e6/l
0.52
79
731
40
292
1.43
1.22
3.9
3.4
2.62
1.95
mmol/l
0.67
35
245
13
222
0.57
1.20
3.7
5.1
0.00
0.22
%
—
6
69
152
1350
1.27
1.20
11.6
16.7
1.28
1.32
inr
0.42
126
1122
39
285
1.43
1.19
2.2
1.8
—
—
—
0
0
5
20
2.53
1.15
1.0
1.1
—
—
—
0
0
30
210
1.48
1.14
4.4
3.3
115.78
84.79
ng/l
0.66
25
179
41
307
1.39
1.10
3.8
3.4
7.36
7.38
ph
1.60
22
183
51
396
1.35
1.10
2.2
2.0
—
—
—
0
0
13
216
0.58
1.09
3.7
4.6
0.86
0.51
%
—
7
76
87
730
1.28
1.08
4.2
3.5
—
0.00
estimate
—
0
6
60
479
1.32
1.08
1.4
1.3
15.99
0.96
u/ml
—
10
127
24
344
0.67
1.08
1.1
1.4
1.28
19.18
u/ml
—
5
119
41
309
1.38
1.06
1.3
1.3
—
—
—
0
0
127
1118
1.24
1.04
6.2
6.2
25.01
25.73
%
0.30
121
1051
20
131
1.57
1.03
3.2
2.9
—
—
—
0
0
10
53
1.92
1.02
2.9
3.5
—
—
—
0
0
66
538
1.29
1.02
2.0
1.7
1146.76
1165.22
nmol/l
0.06
54
409
9
48
1.90
1.01
1.4
1.3
—
—
—
0
0
125
1106
1.23
0.96
6.3
6.1
2.97
2.77
%
0.38
119
1027
125
1107
1.23
0.95
6.5
6.3
8.54
9.02
%
1.17
118
1031
105
915
1.23
0.92
4.7
3.7
61.14
128.89
e6/l
0.41
80
713
52
640
0.77
0.92
3.5
3.7
—
—
—
0
0
54
436
1.29
0.90
1.5
1.5
2.84
2.68
g/l
0.19
27
239
124
1104
1.22
0.88
6.5
6.2
0.65
0.64
%
0.10
118
1026
191
2036
0.81
0.86
4.1
4.6
1.27
1.24
mmol/l
0.28
172
1810
91
788
1.23
0.84
2.8
2.5
55.24
69.27
u/l
0.98
85
732
6
32
1.89
0.82
1.3
1.1
—
—
—
0
0
123
1106
1.20
0.77
6.2
6.1
59.59
58.78
%
0.30
117
1046
6
34
1.78
0.76
1.0
1.4
1.08
0.61
nmol/l
—
6
29
17
116
1.49
0.76
2.5
2.0
902.66
339.42
ug/l
0.50
17
110
9
57
1.60
0.72
1.4
1.2
—
45.00
—
0
6
7
41
1.72
0.70
1.1
1.2
—
—
—
0
0
7
42
1.68
0.69
1.4
1.2
—
—
—
0
0
5
27
1.87
0.68
1.0
1.4
—
—
—
0
0
197
2076
0.84
0.68
5.3
5.3
1.76
2.03
mu/l
2.31
179
1846
209
2190
0.83
0.67
5.6
5.8
6.20
6.13
mmol/l
0.26
190
1966
5
28
1.80
0.66
2.4
2.9
—
—
—
0
0
8
50
1.62
0.62
3.0
4.7
5.30
5.06
kpa
—
8
50
8
50
1.62
0.62
3.0
4.7
8.89
7.89
kpa
—
8
50
5
30
1.68
0.61
3.0
2.4
3.80
5.34
e9/l
—
5
30
5
30
1.68
0.61
1.0
1.4
0.26
0.20
nmol/l
—
5
20
5
30
1.68
0.61
3.2
3.0
2.66
9.13
nmol/l
—
5
30
0
21
0.00
0.60
0.0
1.2
—
—
—
0
0
139
1286
1.16
0.58
3.9
4.6
0.00
5.43
estimate
0.50
27
299
141
1306
1.16
0.58
3.5
3.5
54.95
55.75
u/l
0.04
128
1205
14
98
1.45
0.57
3.1
3.4
25.45
25.35
mmol/l
0.06
14
92
5
88
0.56
0.57
1.2
1.6
—
10.54
—
0
22
230
2213
1.20
0.56
24.3
19.7
29.64
26.66
mg/l
0.73
202
1884
203
2121
0.85
0.56
5.0
5.5
1.45
1.47
mmol/l
0.20
185
1898
18
134
1.37
0.54
3.4
2.9
—
—
—
0
0
9
61
1.49
0.54
1.0
1.1
—
—
—
0
0
13
91
1.45
0.54
3.8
4.9
2.01
3.61
ratio
—
6
52
93
841
1.16
0.52
2.5
2.6
—
—
—
0
0
137
1274
1.14
0.51
3.9
4.5
0.00
0.00
estimate
-0.00
26
290
22
171
1.31
0.51
1.9
2.2
14.69
13.47
nmol/l
0.36
17
150
163
1534
1.14
0.51
6.3
5.2
6.96
6.86
mmol/l
0.21
155
1468
26
208
1.27
0.50
3.2
3.1
5.92
6.06
ph
0.38
20
154
58
659
0.85
0.49
2.8
3.2
339.71
355.75
umol/l
0.53
48
557
88
796
1.15
0.49
4.3
3.6
0.33
0.51
e6/l
0.53
65
596
7
47
1.50
0.48
3.1
2.9
16.00
32.31
u/ml
—
7
47
8
119
0.66
0.46
1.1
1.2
65.27
366.84
u/ml
—
8
109
212
2197
0.87
0.46
6.0
6.5
2.51
2.51
mmol/l
0.01
192
1971
144
1351
1.13
0.46
10.0
9.9
4.49
4.25
e9/l
0.37
117
1173
111
1026
1.13
0.45
3.3
2.9
129.12
139.53
ug/l
0.22
105
932
206
2137
0.87
0.45
5.1
5.6
4.38
4.42
mmol/l
0.24
189
1925
124
1156
1.13
0.43
2.7
3.0
—
—
estimate
—
0
0
5
31
1.62
0.43
2.6
4.3
425.20
347.58
umol/l
—
5
26
5
32
1.57
0.42
1.2
1.1
152.00
388.50
u/ml
—
5
12
5
33
1.52
0.41
1.2
1.1
—
—
—
0
0
138
1298
1.12
0.41
3.9
4.6
0.00
1.10
estimate
0.50
26
272
0
16
0.00
0.41
0.0
2.6
—
7.21
—
0
11
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
31
261
1.21
0.40
6.5
4.0
7.39
7.34
ph
2.35
23
181
67
741
0.88
0.40
4.9
4.5
0.00
0.01
estimate
0.50
22
259
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
10
71
1.42
0.39
3.6
3.1
0.84
0.88
nmol/l
—
10
60
32
375
0.83
0.39
1.3
1.3
13.70
44.11
iu/ml
—
10
130
108
1004
1.12
0.39
3.2
4.0
6.19
6.27
ph
0.28
52
552
101
936
1.12
0.39
2.1
2.3
—
—
—
0
0
12
89
1.36
0.38
5.7
3.2
160.00
199.03
mg/l
—
5
33
208
2148
0.88
0.38
7.2
7.4
40.06
40.52
mmol/mol
0.30
188
1981
8
115
0.69
0.37
1.1
1.3
—
—
—
0
0
62
559
1.14
0.36
4.3
4.9
1.02
1.02
kg/l
0.04
49
390
131
1237
1.11
0.35
6.4
6.2
0.19
0.19
e9/l
0.00
106
1063
127
1198
1.11
0.35
6.1
6.0
0.59
0.60
e9/l
0.27
101
1020
89
958
0.90
0.34
5.4
5.9
4.92
2.93
ug/l
0.30
78
847
85
917
0.90
0.34
4.4
3.4
95.76
53.80
mg/l
0.46
60
604
6
90
0.66
0.33
10.8
10.3
—
—
—
0
0
6
47
1.28
0.32
2.8
2.6
58.83
60.40
%
—
6
47
104
1107
0.91
0.32
3.8
4.5
80.25
45.05
ng/l
0.63
82
905
65
596
1.12
0.30
3.9
4.2
—
0.25
—
0
12
127
1207
1.09
0.29
6.1
6.0
0.04
0.04
e9/l
0.10
101
1029
51
560
0.89
0.28
2.7
3.4
0.93
0.83
ug/l
0.41
36
408
11
86
1.29
0.26
1.5
1.5
—
11.04
—
0
11
5
71
0.70
0.26
1.0
1.2
—
—
—
0
0
5
72
0.69
0.26
1.0
1.2
—
—
—
0
0
9
74
1.22
0.25
1.4
1.2
—
3.83
—
0
7
89
944
0.92
0.25
5.2
4.0
19.78
9.39
mg/mmol
0.52
56
591
11
137
0.80
0.25
2.2
2.6
—
—
—
0
0
97
918
1.09
0.24
2.0
2.0
1.24
1.26
mmol/l
0.11
86
738
5
38
1.32
0.23
1.8
1.1
4.18
9.35
u/l
—
5
29
62
577
1.10
0.22
1.9
1.8
459.90
434.20
pmol/l
0.27
50
480
5
42
1.19
0.21
2.6
5.3
8.64
11.91
mg/l
—
5
37
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
34.10
—
0
5
0
10
0.00
0.21
0.0
5.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
189.00
—
0
12
5
43
1.17
0.21
1.8
2.5
35.20
32.72
pg
—
5
43
27
240
1.14
0.21
4.0
2.6
0.28
0.89
e6/l
0.83
27
227
127
1221
1.07
0.21
6.1
6.1
1.63
1.88
e9/l
1.59
105
1074
0
13
0.00
0.21
0.0
1.3
—
0.79
—
0
5
9
112
0.80
0.20
1.2
2.8
4.46
4.25
pmol/l
—
9
100
9
113
0.79
0.20
1.3
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
6
50
1.20
0.20
1.0
1.3
—
—
—
0
0
21
185
1.15
0.18
1.6
1.5
—
—
—
0
0
64
605
1.07
0.16
1.2
1.3
—
—
—
0
0
26
287
0.90
0.16
1.3
1.3
240.00
565.80
titre
—
7
69
19
214
0.88
0.16
3.1
4.4
1.24
1.22
mmol/l
1.42
14
188
8
73
1.10
0.16
4.0
1.7
—
—
—
0
0
9
81
1.11
0.15
2.9
4.1
7.41
7.41
ph
—
9
81
28
305
0.91
0.14
1.8
1.4
—
—
—
0
0
12
139
0.86
0.14
1.8
1.3
—
—
—
0
0
8
97
0.82
0.14
1.0
1.1
—
—
—
0
0
28
258
1.09
0.13
2.3
2.1
227.37
147.15
ug/g
0.43
19
211
60
572
1.06
0.12
2.9
3.4
528.37
537.84
mosm/kgh2o
0.16
55
503
17
188
0.90
0.11
1.4
2.9
138.06
127.81
g/l
1.05
17
183
108
1051
1.04
0.11
11.7
12.9
0.00
0.00
e9/l
0.64
78
870
27
251
1.08
0.10
3.0
2.1
377.11
377.71
nmol/l
0.01
27
236
23
212
1.09
0.10
4.8
3.0
—
—
—
0
0
5
46
1.09
0.09
2.6
2.9
9.10
9.75
pmol/l
—
5
46
24
223
1.08
0.09
1.5
1.4
—
—
—
0
0
27
288
0.93
0.09
1.8
1.3
—
—
—
0
0
94
964
0.96
0.08
4.2
4.6
0.00
0.03
estimate
1.23
21
244
31
294
1.06
0.07
2.9
3.0
73.48
68.37
e9/l
0.18
18
225
40
383
1.05
0.07
2.5
2.9
1.67
1.78
%
0.30
33
344
11
122
0.90
0.07
1.8
1.3
—
60.15
—
0
10
70
681
1.04
0.07
3.5
4.2
0.00
0.12
estimate
0.55
21
229
237
2354
1.04
0.06
33.8
29.6
7.15
6.96
e9/l
0.52
228
2292
237
2354
1.04
0.06
33.8
29.6
4.30
4.39
e12/l
1.65
227
2291
237
2354
1.04
0.06
33.4
29.6
255.12
240.10
e9/l
2.52
227
2305
88
862
1.03
0.06
2.7
2.2
499.19
226.24
u/l
0.45
80
814
225
2236
1.03
0.04
18.7
17.7
—
—
—
0
0
35
338
1.04
0.04
1.3
1.2
—
—
—
0
0
167
1655
1.02
0.04
4.4
4.8
—
0.20
—
0
5
229
2303
0.97
0.04
14.4
13.5
26.75
23.85
u/l
1.27
221
2219
15
141
1.07
0.03
1.1
1.3
—
—
—
0
0
24
231
1.04
0.03
1.7
1.4
—
—
—
0
0
13
122
1.07
0.02
1.9
1.9
—
—
—
0
0
16
166
0.96
0.00
1.6
2.4
0.56
0.63
%
0.30
16
166
55
548
1.00
0.00
1.5
1.7
1.20
1.62
mg/l
0.86
47
442
19
189
1.01
0.00
4.9
4.2
—
—
—
0
0
92
921
1.00
0.00
4.2
3.3
6.40
7.22
mmol/l
1.43
78
763
23
234
0.98
0.00
1.7
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
3.8
—
52.83
—
0
6
0
5
0.00
-0.00
0.0
3.2
—
1.06
—
0
5
0
5
0.00
-0.00
0.0
3.6
—
6.24
—
0
5
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
5
51
0.98
-0.00
3.2
2.6
0.54
0.89
%
—
5
33
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
6.3
—
—
—
0
0
17
170
1.00
-0.00
1.5
2.5
1.34
1.11
%
0.64
17
170
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.6
—
0.69
—
0
5
0
9
0.00
-0.00
0.0
3.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
0.00
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
20.80
—
0
5

Mortality – FinRegistry

↥

Association

Association between endpoint AB1_SEQULAE_POLIO and mortality.

Females

Parameter HR [95% CI] p-value
AB1_SEQULAE_POLIO 1.391 [1.15, 1.68] < 0.001
Birth year 0.995 [0.99, 1.0] 0.261

During the follow-up period (1.1.1998 — 31.12.2019), 218 out of 652 females with AB1_SEQULAE_POLIO died.

Males

Parameter HR [95% CI] p-value
AB1_SEQULAE_POLIO 1.694 [1.4, 2.05] < 0.001
Birth year 0.988 [0.98, 1.0] 0.01

During the follow-up period (1.1.1998 — 31.12.2019), 273 out of 623 males with AB1_SEQULAE_POLIO died.

Mortality risk

Mortality risk for people of age

years, who have AB1_SEQULAE_POLIO.

N-year risk Females Males
1 0.116% 0.295%
5 0.895% 1.986%
10 2.244% 4.869%
15 4.346% 9.197%
20 7.669% 15.654%

Relationships between endpoints

↥

Index endpoint: AB1_SEQULAE_POLIO – Sequelae of poliomyelitis

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data